[
    [
        {
            "time": "",
            "original_text": "东吴医药行业周观点：药明康德成为第二家“IPO快速通道”的独角兽公司 创新药主题迎来新一轮投资机会",
            "features": {
                "keywords": [
                    "药明康德",
                    "IPO快速通道",
                    "独角兽",
                    "创新药",
                    "投资机会"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "东吴医药行业周观点：药明康德成为第二家“IPO快速通道”的独角兽公司 创新药主题迎来新一轮投资机会",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[买入评级] 医药生物行业深度研究：医药市场认可提升 优选高景气子行业龙头",
            "features": {
                "keywords": [
                    "买入评级",
                    "医药生物",
                    "市场认可",
                    "高景气",
                    "子行业龙头"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[买入评级] 医药生物行业深度研究：医药市场认可提升 优选高景气子行业龙头",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[强于大市评级] 医药生物行业投资策略：从工业数据窥见医药行业配置意义与投资价值",
            "features": {
                "keywords": [
                    "强于大市评级",
                    "医药生物",
                    "投资策略",
                    "工业数据",
                    "配置意义",
                    "投资价值"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[强于大市评级] 医药生物行业投资策略：从工业数据窥见医药行业配置意义与投资价值",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]